Evaluate Forecasting Excellence:
The Value of Outliers in Consensus Forecasting

DOWNLOAD THE VALUE OF OUTLIERS IN CONSENSUS FORECASTING

A perspective on the portfolio strategy of the top 20 pharma companies

Evaluate Forecasting Excellence: The Value of Outliers in Consensus Forecasting analyses the portfolio strategy of the top 20 pharmaceutical companies by leveraging the maximum and minimum forecast within EvaluatePharma® consensus.

Themes of the report include:

  • Upside/downside ratio metrics that identify companies that could either outperform in the coming years or are at risk.
  • Companies that could follow a different trajectory compared to the scenario outlined by consensus forecasts.
  • More details on the value of a company’s pipeline for which forecasts are not yet available.


The Value of Outliers in Consensus Forecasting is the first report in the  Evaluate Forecasting Excellence series which aims to improve forecasting accuracy to drive more robust decision-making, allocate investment more efficiently and ultimately drive continuous innovation.



Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry.

Download Report

Europe
Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7539 1801
North america
Tel: 1-617-573-9450
Fax: 1-617-573-9542
japan
Tel: +81 (0)80-1164-4754
TWITTER
LINKEDIN
EMAIL
Privacy policy